Cytomegalovirus (CMV)

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

The Basics | Prevention | Treatment | Personal Accounts | Research

The Basics

Cytomegalovirus (CMV) (October 2007)
To read PDF, click here
From Project Inform
Cytomegalovirus (CMV) (August 15, 2006)
From AIDS Treatment Data Network
Cytomegalovirus and HIV (May 2006)
From HIV InSite
Cytomegalovirus (CMV) (February 26, 2005)
To read PDF, click here
From AIDS InfoNet
What is CMV? (June 10, 2003)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
Cytomegalovirus Retinitis in 2003 (May 2003)
Even with the advent of HAART, CMV disease continues to be an important clinical problem in people living with HIV.
In Hopkins HIV Report
Cytomegalovirus (CMV) and You (April 2003)
A guide for people with HIV infection.
From U.S. Centers for Disease Control and Prevention
Patient/Doctor Q&A: CMV, Cervical Cancer, MRSA and Low Platelets (September 2002)
To read PDF, click here
In HIV Treatment ALERTS!, from The Center for AIDS
Save Your Sight: Eye Disease and HIV (December 2001/January 2002)
In Positive Living, from AIDS Project Los Angeles
Eye Diagram (May 1998)
From U.S. National Institutes of Health
Eye Problems (Summer 1997)
In Women Alive Newsletter, from Women Alive
CMV Background (April/May 1997)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Cidofovir Reaches Drugstores (August 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
CMV Retinitis and Treatment: CME Course on World Wide Web (July 5, 1996)
In AIDS Treatment News, from AIDS Treatment News
How to Help Yourself: AIDS-Related CMV (January 1994)
From U.S. National Institute of Allergy and Infectious Diseases
AIDS, HIV, and the Eye
From American Academy of Ophthalmology
The Amsler Grid and Other Self-Tests for CMV Reinitis
From AIDS Research Information Center

Prevention

Loss of Cytomegalovirus-Specific CD4 T Cell Responses in Human Immunodeficiency Virus Type-1-Infected Patients with High CD4 T Cell Counts and Recurrent Retinitis (April 25, 2001)
In Journal of Infectious Diseases
Withdrawing Secondary CMV Prophylaxis (August 1998)
In HIV Newsline, from San Francisco General Hospital
Combination Therapy May Stave Off Further Bouts of CMV Retinitis (June 1998)
In AIDS Care, from San Francisco General Hospital
CMV Prophylaxis Quandary (December 1995)
In TAGline, from Treatment Action Group
CMV: Oral Ganciclovir for Prevention (November 3, 1995)
In AIDS Treatment News, from AIDS Treatment News

Treatment

Cidofovir (Vistide, HPMPC) (August 15, 2006)
From AIDS Treatment Data Network
Ganciclovir Implants (Vitrasert) (August 15, 2006)
From AIDS Treatment Data Network
Oral Ganciclovir (Cytovene) (August 15, 2006)
From AIDS Treatment Data Network
Cytomegalovirus Disease (December 17, 2004)
A chapter from "Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents" guidelines.
To read PDF, click here
In Morbidity and Mortality Weekly Report, from U.S. Centers for Disease Control and Prevention
An Overview of Ganciclovir (Cytovene, Vitrasert) (September 28, 2004)
To read PDF, click here
From U.S. National Institutes of Health
Valganciclovir: A New Treatment for Cytomegalovirus Retinitis (Winter 2002/2003)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
2002 Safety Alert: Cytovene IV (Ganciclovir Sodium for Injection) (February 13, 2002)
From U.S. Food and Drug Administration
Valganciclovir Recommended for Approval (April 2001)
In What's New, from Project Inform
Advances in CMV Management: Fomivirsen (Vitravene®) Approved (December 1998)
In Project Inform Perspective, from Project Inform
New CMV Retinitis Drug Approved (October 1998)
In Body Positive, from Body Positive
Fomivirsen Approved for CMV Retinitis: First Antisense Drug (September 4, 1998)
From AIDS Treatment News
Approval Letter for the Use of Vitravene Injection for the Local Treatment of Cytomegalovirus (CMV) Retinitis (August 28, 1998)
From U.S. Food and Drug Administration
Better Treatment for CMV Retinitis: An Update (August 1998)
In HIV Newsline, from San Francisco General Hospital
Improved Treatment of CMV Retinitis (February 1998)
In HIV Newsline, from San Francisco General Hospital
CMV Viremia: A Look at the Other Viral Load (December 1997/January 1998)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Improved Ganciclovir Regimens (December 1997/January 1998)
In GMHC Treatment Issues, from Gay Men's Health Crisis
The Vitrasert Ganciclovir Implant's Place in the CMV Treatment Line Up (April/May 1997)
In GMHC Treatment Issues, from Gay Men's Health Crisis
The State of the Art: Treatment of CMV Disease (Spring 1997)
A comprehensive report.
In Direct Information on Research and Treatment Newsletter, from ARIC
Cidofovir Warning (October 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Cidofovir Recommended for Approval for CMV Retinitis (April 5, 1996)
In AIDS Treatment News, from AIDS Treatment News
New Developments in the Management of CMV Infections (April 1996)
In HIV Newsline, from San Francisco General Hospital
CMV: The Other Virus (March 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
New Drug Recommended for Treament of CMV Retinitis (Spring 1996)
In STEP Perspective, from Seattle Treatment Education Project
And Also, "Adefovir Dipovixil" (February 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Finding a Place for Cidofovir (January 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Oral Ganciclovir (Winter 1995)
In STEP Perspective, from Seattle Treatment Education Project
Ganciclovir for CMV Retinitis (Summer 1995)
In STEP Perspective, from Seattle Treatment Education Project
New Treatments, New Hope in Avoiding Blindness (June 1995)
From American Foundation for AIDS Research

Personal Accounts

My Journey of Transformation (January/February 2003)
José María Medellín reflects on his HIV-related vision impairment.
In Body Positive, from Body Positive
Sight Is Not a Prerequisite for Designer Eric Brun-Sanglard's Success (December 1999)
In Positive Living, from AIDS Project Los Angeles
A Vision of the Future (August 1997)
In Body Positive, from Body Positive

Research

CMV Levels May Predict HIV Disease Progression (October 2004)
Quick recap of a study in The Lancet.
In HIV Treatment ALERTS!, from The Center for AIDS
HAART Good for Vision and Quality of Life, Studies Find (June 18, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
A Synergistic Effect of HIV and CMV Infection/Reactivation on Response to HAART and Plasma CD8+/CD38+ But Not CD4+ Cell Populations in Patients With Primary HIV Infection (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO
Oral Valganciclovir as Effective as IV Ganciclovir in Treating CMV Retinitis in AIDS Patients (April 12, 2002)
Results of a recent Emory University study.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Discontinuation of Maintenance Therapy for Cytomegalovirus Retinitis in HIV-Infected Patients Who Have Responded to Highly Active Antiretroviral Therapy (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Needleless Retinitis Therapy with FDA Approval of Oral CMV Drug (April 2001)
In TAGline, from Treatment Action Group
Advances in Treating CMV (August 2000)
In Project Inform Perspective, from Project Inform
Long-Term Effects of HAART on Morbidity and Mortality in HIV-1-Infected Patients at Risk for CMV Disease (January 31, 2000)
In The 7th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Multicenter Evaluation of CMV Reactivation in HIV-infected Women at Potential Risk for CMV Disease (January 31, 2000)
In The 7th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Anti-HIV Treatment Improves Immune System and Fights Sight-Threatening Eye Infection (November 2, 1999)
From U.S. National Institutes of Health
Update: Treatment of CMV Retinitis (October 1999)
In HIV Newsline, from San Francisco General Hospital
A New Acronym, a New Threat: IRU (September 1999)
In Project Inform Perspective, from Project Inform
Secondary Prophylaxis for CMV Retinitis (August 1999)
In HIV Newsline, from San Francisco General Hospital
HIV-Related Clinical Updates: CMV/Cytomegalovirus Disease (May 2, 1998)
In The 8th Clinical Care Options for HIV Symposium, from The Body PRO
Impact of Highly Active Antiretroviral Therapy on Opportunistic Infections (3 abstracts) (September 28-October 1, 1997)
In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
CMV Trials Struggle to Enroll (September 1997)
In GMHC Treatment Issues, from Gay Men's Health Crisis
CMV: Pathogenesis, Viral Load and Prophylaxis Treatment Strategies (June 1997)
In The 7th Annual Clinical Care Options for HIV Symposium, from The Body PRO
CMV Retinitis, Newly Diagnosed: RS-79070 Trial (May 1, 1997)
From AIDS Treatment News
CMV, RS-79070: Community Concern As Major Drug's Development Suspended (May 1, 1997)
From AIDS Treatment News
Combination Drug Therapy for AIDS Found to Control Blinding Eye Infection (May 1997)
From U.S. National Institutes of Health
Ganciclovir Prodrug Development Program Languishes While Roche Determines Market Demand (April/May 1997)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Treatment of CMV Retinitis (March 1997)
In Hopkins HIV Report, from Johns Hopkins AIDS Service
CMV Retinitis Despite High CD4 Lymphocyte Counts (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Lobucavir (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
CPCRA v. Syntex (November 1996)
Effect of ddI on Ganciclovir may explain disparity between two prophylaxis studies.
From Treatment Action Group
Cytomegalovirus: Report from the The Third International Conference on Drug Therapy in HIV Infection (November 1996)
In Journal of the International Association of Physicians in AIDS Care, from International Association of Physicians in AIDS Care
Responding to CMV Neurologic Infections (November 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
CMV Information: Print, Online, Phone, Video (October 1996)
In AIDS Treatment News, from AIDS Treatment News
CMV Retinitis Study Aborted (September 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Combination of Ganciclovir and Foscarnet Better than Monotherapy for Retinitis (April 1996)
In HIV Newsline, from San Francisco General Hospital
Cytomegalovirus Retinitis: New Approaches (March 1996)
In Moore News for Care Providers, from Johns Hopkins AIDS Service

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.